Advanced search
Publication Cover
Pharmacogenomics Volume 7, 2006 - Issue 5
Submit an article Journal homepage
317
Views
0
CrossRef citations to date
0
Altmetric
Review

Pharmacogenetics of Alkylator-Associated Acute Myeloid Leukemia

Eric Knoche1 Washington University School of Medicine, Division of Oncology, Stem Cell Biology Section, Campus Box 8007, 660 South Euclid Avenue, St Louis, MO63110, USA. Tel: +1 314 747 4437; Fax: +1 314 362 9333;[email protected]View further author information
,
Howard L McLeod1 Washington University School of Medicine, Division of Oncology, Stem Cell Biology Section, Campus Box 8007, 660 South Euclid Avenue, St Louis, MO63110, USA. Tel: +1 314 747 4437; Fax: +1 314 362 9333;[email protected]View further author information
&
Timothy A Graubert1 Washington University School of Medicine, Division of Oncology, Stem Cell Biology Section, Campus Box 8007, 660 South Euclid Avenue, St Louis, MO63110, USA. Tel: +1 314 747 4437; Fax: +1 314 362 9333;[email protected]View further author information
Pages 719-729 | Published online: 03 Aug 2006

Bibliography

  • Bhatia S , SklarC: Second cancers in survivors of childhood cancer.Nature Rev. Cancer2, 124–132 (2002).
  • Leone G , VosoMT, SicaS, MorosettiR, PaganoL: Therapy-related leukemias: susceptibility, prevention and treatment.Leuk. Lymphoma41, 255–276 (2001).
  • Schoch C , KernW, SchnittgerS, HiddemannW, HaferlachT: Karyotype is an independent prognostic parameter in therapy-related acute myeloid leukemia (t-AML): an analysis of 93 patients with t-AML in comparison to 1091 patients with de novo AML.Leukemia18, 120–125 (2004).
  • van L eeuwen FE, Chorus AM, van den Belt-Dusebout AW et al.: Leukemia risk following Hodgkin's disease: relation to cumulative dose of alkylating agents, treatment with teniposide combinations, number of episodes of chemotherapy, and bone marrow damage. J. Clin. Oncol.12, 1063–1073 (1994).
  • Larson RA , Le Beau MM: Therapy-related myeloid leukaemia: a model for leukemogenesis in humans. Chem. Biol. Interact.153–154, 187–195 (2005).
  • Frohling S , SchollC, GillilandDG, Levine RL: Genetics of myeloid malignancies: pathogenetic and clinical implications. J. Clin. Oncol.23, 6285–6295 (2005).
  • Bertram L , TanziRE: The genetic epidemiology of neurodegenerative disease.J. Clin. Invest.115, 1449–1457 (2005).
  • Permutt MA , WassonJ, CoxN: Genetic epidemiology of diabetes.J. Clin. Invest.115, 1431–1439 (2005).
  • Side L , TaylorB, CayouetteM et al.: Homozygous inactivation of the NF1gene in bone marrow cells from children with neurofibromatosis type 1 and malignant myeloid disorders. N. Engl. J. Med.336, 1713–1720 (1997).
  • Jacks T , ShihTS, SchmittEM, BronsonRT, BernardsA, WeinbergRA: Tumour predisposition in mice heterozygous for a targeted mutation in Nf1.Nature Genet.7, 353–361 (1994).
  • Papageorgio C , SeiterK, FeldmanEJ: Therapy-related myelodysplastic syndrome in adults with neurofibromatosis.Leuk. Lymphoma32, 605–608 (1999).
  • Mahgoub N , TaylorBR, Le Beau MM et al.: Myeloid malignancies induced by alkylating agents in Nf1 mice. Blood93, 3617–3623 (1999).
  • Chao RC , PyzelU, FridlyandJ et al.: Therapy-induced malignant neoplasms in Nf1 mutant mice. Cancer Cell8, 337–348 (2005).
  • Wang Q , StacyT, BinderM, Marin-Padilla M, Sharpe AH, Speck NA: Disruption of the Cbfa2 gene causes necrosis and hemorrhaging in the central nervous system and blocks definitive hematopoiesis. Proc. Natl Acad. Sci. USA93, 3444–3449 (1996).
  • Okuda T , van Deursen J, Hiebert SW, Grosveld G, Downing JR: AML1, the target of multiple chromosomal translocations in human leukemia, is essential for normal fetal liver hematopoiesis. Cell84, 321–330 (1996).
  • Song WJ , SullivanMG, LegareRD et al.: Haploinsufficiency of CBFA2 causes familial thrombocytopenia with propensity to develop acute myelogenous leukemia. Nature Genet.23, 166–175 (1999).
  • Roumier C , FenauxP, LafageM, ImbertM, EclacheV, PreudhommeC: New mechanisms of AML1 gene alteration in hematological malignancies.Leukemia17, 9–16 (2003).
  • Osato M : Point mutations in the RUNX1/AML1 gene: another factor in RUNX leukemia.Oncogene23, 4284–4296 (2004).
  • Harada H , HaradaY, NiimiH, KyoT, KimuraA, InabaT: High incidence of somatic mutations in the AML1/RUNX1 gene in myelodysplastic syndrome and low blast percentage myeloid leukemia with myelodysplasia.Blood103, 2316–2324 (2004).
  • Zhang DE , ZhangP, WangND, HetheringtonCJ, DarlingtonGJ, Tenen DG: Absence of granulocyte colony-stimulating factor signaling and neutrophil development in CCAAT enhancer binding protein α-deficient mice. Proc. Natl Acad. Sci. USA94, 569–574 (1997).
  • Zhang P , J Iwasaki-Arai, Iwasaki H et al.: Enhancement of hematopoietic stem cell repopulating capacity and self-renewal in the absence of the transcription factor C/EBP α. Immunity21, 853–863 (2004).
  • Porse BT , BryderD, K Theilgaard-Monch et al.: Loss of C/EBP α cell cycle control increases myeloid progenitor proliferation and transforms the neutrophil granulocyte lineage. J. Exp. Med.202, 85–96 (2005).
  • Smith ML , CavenaghJD, ListerTA, FitzgibbonJ: Mutation of CEBPA in familial acute myeloid leukemia.N. Engl. J. Med.351, 2403–2407 (2004).
  • Sellick GS , SpendloveHE, CatovskyD, Pritchard-JonesK, HoulstonRS: Further evidence that germline CEBPA mutations cause dominant inheritance of acute myeloid leukaemia.Leukemia19, 1276–1278 (2005).
  • Pabst T , MuellerBU, ZhangP et al.: Dominant-negative mutations of CEBPA, encoding CCAAT/enhancer binding protein-α (C/EBPα), in acute myeloid leukemia. Nature Genet.27, 263–70 (2001).
  • Preudhomme C , SagotC, BoisselN et al.: Favorable prognostic significance ofCEBPA mutations in patients with de novo acute myeloid leukemia: a study from the Acute Leukemia French Association (ALFA). Blood100, 2717–2723 (2002).
  • Pabst T , MuellerBU, HarakawaN et al.: AML1-ETO downregulates the granulocytic differentiation factor C/EBPα in t(8;21) myeloid leukemia. Nature Med.7, 444–451 (2001).
  • Radomska HS , BasseresDS, ZhengR et al.: Block of C/EBPα function by phosphorylation in acute myeloid leukemia with FLT3 activating mutations. J. Exp. Med.203, 371–381 (2006).
  • Kaeferstein A , KrugU, TiesmeierJ et al.: The emergence of a C/EBPα mutation in the clonal evolution of MDS towards secondary AML. Leukemia17, 343–349 (2003).
  • Scott EW , SimonMC, AnastasiJ, SinghH: Requirement of transcription factor PU.1 in the development of multiple hematopoietic lineages.Science265, 1573–1577 (1994).
  • Dakic A , MetcalfD, L Di Rago, Mifsud S, Wu L, Nutt SL: PU.1 regulates the commitment of adult hematopoietic progenitors and restricts granulopoiesis. J. Exp. Med.201, 1487–1502 (2005).
  • Rosenbauer F , WagnerK, KutokJL et al.: Acute myeloid leukemia induced by graded reduction of a lineage-specific transcription factor, PU.1. Nature Genet.36, 624–630 (2004).
  • Walter MJ , ParkJS, RiesRE et al.: Reduced PU.1 expression causes myeloid progenitor expansion and increased leukemia penetrance in mice expressing PML-RARα. Proc. Natl Acad. Sci. USA102, 12513–12518 (2005).
  • Vangala RK , Heiss-NeumannMS, Rangatia JS et al.: The myeloid master regulator transcription factor PU.1 is inactivated by AML1-ETO in t(8;21) myeloid leukemia. Blood101, 270–277 (2003).
  • Cook WD , McCawBJ, HerringC et al.: PU.1 is a suppressor of myeloid leukemia, inactivated in mice by gene deletion and mutation of its DNA binding domain. Blood104, 3437–3444 (2004).
  • Moreau-Gachelin F , TavitianA, Tambourin P: Spi-1 is a putative oncogene in virally induced murine erythroleukemias. Nature331, 277–280 (1988).
  • Moreau-Gachelin F , WendlingF, MolinaT et al.: Spi-1/PU.1 transgenic mice develop multistep erythroleukemias. Mol. Cell. Biol.16, 2453–2463 (1996).
  • Mueller BU , PabstT, OsatoM et al.: Heterozygous PU.1 mutations are associated with acute myeloid leukemia. Blood100, 998–1007 (2002).
  • Dohner K , TobisK, BischofT et al.: Mutation analysis of the transcription factor PU.1 in younger adults (16 to 60 years) with acute myeloid leukemia: a study of the AML Study Group Ulm (AMLSG ULM). Blood102, 3850–3851 (2003).
  • Lamandin C , SagotC, RoumierC et al.: Are PU.1 mutations frequent genetic events in acute myeloid leukemia (AML)? Blood100, 4680–4681 (2002).
  • Suraweera N , MeijneE, MoodyJ et al.: Mutations of the PU.1 Ets domain are specifically associated with murine radiation-induced, but not human therapy-related, acute myeloid leukaemia. Oncogene24, 3678–3683 (2005).
  • Qu CK , ShiZQ, ShenR, TsaiFY, Orkin SH, Feng GS: A deletion mutation in the SH2-N domain of Shp-2 severely suppresses hematopoietic cell development. Mol. Cell Biol.17, 5499–5507 (1997).
  • Tartaglia M , MehlerEL, GoldbergR et al.: Mutations in PTPN11, encoding the protein tyrosine phosphatase SHP-2, cause Noonan syndrome. Nature Genet.29, 465–468 (2001).
  • Mohi MG , WilliamsIR, DearolfCR et al.: Prognostic, therapeutic, and mechanistic implications of a mouse model of leukemia evoked by Shp2 (PTPN11) mutations. Cancer Cell7, 179–191 (2005).
  • Loh ML , ReynoldsMG, VattikutiS et al.: PTPN11 mutations in pediatric patients with acute myeloid leukemia: results from the Children's Cancer Group. Leukemia18, 1831–1834 (2004).
  • Chantrain CF , JijonP, T De Raedt et al.: Therapy-related acute myeloid leukemia in a child with Noonan syndrome and clonal duplication of the germline PTPN11 mutation. Pediatr. Blood Cancer (Epub ahead of print) (2005).
  • Bacher U , HaferlachT, SchochC, KernW, SchnittgerS: NRAS mutations in AML: biology, cytogenetics, and prognosis – a study on 2502 patients.Blood (2006).
  • Bowen DT , FrewME, HillsR et al.: RAS mutation in acute myeloid leukemia is associated with distinct cytogenetic subgroups but does not influence outcome in patients younger than 60 years. Blood106, 2113–2119 (2005).
  • Christiansen DH , AndersenMK, DestaF, Pedersen-BjergaardJ: Mutations of genes in the receptor tyrosine kinase (RTK)/RAS–BRAF signal transduction pathway in therapy-related myelodysplasia and acute myeloid leukemia.Leukemia19, 2232–2240 (2005).
  • Malkinson AM : Molecular comparison of human and mouse pulmonary adenocarcinomas.Exp. Lung Res.24, 541–555 (1998).
  • Braun BS , TuvesonDA, KongN et al.: Somatic activation of oncogenic Kras in hematopoietic cells initiates a rapidly fatal myeloproliferative disorder. Proc. Natl Acad. Sci. USA101, 597–602 (2004).
  • Hisada M , GarberJE, FungCY, Fraumeni JF Jr, Li FP: Multiple primary cancers in families with Li-Fraumeni syndrome. J. Natl Cancer Inst.90, 606–611 (1998).
  • Dumont P , LeuJI, Della Pietra AC 3rd, George DL, Murphy M: The codon 72 polymorphic variants of p53 have markedly different apoptotic potential. Nature Genet.33, 357–365 (2003).
  • Linggi B , C Muller-Tidow, L van de Locht et al.: The t(8;21) fusion protein, AML1 ETO, specifically represses the transcription of the p14(ARF) tumor suppressor in acute myeloid leukemia. Nature Med.8, 743–750 (2002).
  • Christiansen DH , AndersenMK, Pedersen-BjergaardJ: Mutations with loss of heterozygosity of p53 are common in therapy-related myelodysplasia and acute myeloid leukemia after exposure to alkylating agents and significantly associated with deletion or loss of 5q, a complex karyotype, and a poor prognosis.J. Clin. Oncol.19, 1405–1413 (2001).
  • Side LE , CurtissNP, TeelK et al.: RAS, FLT3, and TP53 mutations in therapy-related myeloid malignancies with abnormalities of chromosomes 5 and 7. Genes Chromosomes Cancer39, 217–223 (2004).
  • Taniguchi T , AD D'Andrea: The molecular pathogenesis of fanconi anemia: recent progress. Blood (2006).
  • Kutler DI , SinghB, SatagopanJ et al.: A 20-year perspective on the International Fanconi Anemia Registry (IFAR). Blood101, 1249–1256 (2003).
  • Tischkowitz MD , MorganNV, Grimwade D et al.: Deletion and reduced expression of the Fanconi anemia FANCA gene in sporadic acute myeloid leukemia. Leukemia18, 420–425 (2004).
  • Lensch MW , TischkowitzM, Christianson TA et al.: Acquired FANCA dysfunction and cytogenetic instability in adult acute myelogenous leukemia. Blood102, 7–16 (2003).
  • King-Underwood L , RenshawJ, Pritchard-Jones K: Mutations in the Wilms' tumor gene WT1 in leukemias. Blood87, 2171–2179 (1996).
  • Takahashi T , YamamotoR, TanakaK, KamadaN, MiyagawaK: Mutation analysis of the WT1 gene in secondary leukemia.Leukemia14, 1316–1317 (2000).
  • Shearer P , KapoorG, BeckwithJB, TakashimaJ, BreslowN, GreenDM: Secondary acute myelogenous leukemia in patients previously treated for childhood renal tumors: a report from the National Wilms Tumor Study Group.J. Pediatr. Hematol. Oncol.23, 109–111 (2001).
  • Nichols KE , LevitzS, ShannonKE et al.: Heterozygous germline ATMmutations do not contribute to radiation-associated malignancies after Hodgkin's disease. J. Clin. Oncol.17, 1259 (1999).
  • Meadows AT , BaumE, F Fossati-Bellani et al.: Second malignant neoplasms in children: an update from the Late Effects Study Group. J. Clin. Oncol.3, 532–538 (1985).
  • Crispino JD : GATA1 in normal and malignant hematopoiesis.Semin. Cell Dev. Biol.16, 137–147 (2005).
  • Ahmed M , SternbergA, HallG et al.: Natural history of GATA1 mutations in Down syndrome. Blood103, 2480–2489 (2004).
  • Greene ME , MundschauG, WechslerJ et al.: Mutations in GATA1 in both transient myeloproliferative disorder and acute megakaryoblastic leukemia of Down syndrome. Blood Cells Mol. Dis.31, 351–356 (2003).
  • Harigae H , XuG, SugawaraT, IshikawaI, TokiT, ItoE: The GATA1 mutation in an adult patient with acute megakaryoblastic leukemia not accompanying Down syndrome.Blood103, 3242–3243 (2004).
  • Ley TJ , MinxPJ, WalterMJ et al.: A pilot study of high-throughput, sequence-based mutational profiling of primary human acute myeloid leukemia cell genomes. Proc. Natl Acad. Sci. USA100, 14275–14280 (2003).
  • Allan JM , RabkinCS: Genetic susceptibility to iatrogenic malignancy.Pharmacogenomics6, 615–628 (2005).
  • Felix CA , WalkerAH, LangeBJ et al.: Association of the CYP3A4 genotype with treatment-related leukemia. Proc. Natl Acad. Sci. USA95, 13176–13181 (1998).
  • Roddam PL , AllanJM, RollinsonS et al.: Poor metabolizer status at the cytochrome P450 2C9 and 2D6 loci does not modulate susceptibility to therapy-related acute myeloid leukaemia. Br. J. Haematol.121, 192–194 (2003).
  • Allan JM , WildCP, RollinsonS et al.: Polymorphism in glutathione S-transferase P1 is associated with susceptibility to chemotherapy-induced leukemia. Proc. Natl Acad. Sci. USA98, 11592–11597 (2001).
  • Allan JM , SmithAG, WheatleyK et al.: Genetic variation in XPD predicts treatment outcome and risk of acute myeloid leukemia following chemotherapy. Blood104, 3872–3877 (2004).
  • Worrillow LJ , TravisLB, SmithAG et al.: An intron splice acceptor polymorphism in hMSH2 and risk of leukemia after treatment with chemotherapeutic alkylating agents. Clin. Cancer Res.9, 3012–3020 (2003).
  • Seedhouse C , BaintonR, LewisM, Harding A, Russell N, Das-Gupta E: The genotype distribution of the XRCC1 gene indicates a role for base excision repair in the development of therapy-related acute myeloblastic leukemia. Blood100, 3761–3766 (2002).
  • Fenske TS , McMahonC, EdwinD et al.: Identification of candidate alkylator-induced cancer susceptibility genes by whole genome scanning in mice. Cancer Res.66, 5029–5038 (2006).
  • Watanabe D , EzoeS, FujimotoM et al.: Suppressor of cytokine signalling-1 gene silencing in acute myeloid leukaemia and human haematopoietic cell lines. Br. J. Haematol.126, 726–735 (2004).
  • Weng AP , FerrandoAA, LeeW et al.: Activating mutations of NOTCH1 in human T cell acute lymphoblastic leukemia. Science306, 269–271 (2004).
  • Wolfler A , ErkelandSJ, BodnerC et al.: A functional single-nucleotide polymorphism of the G-CSF receptor gene predisposes individuals to high-risk myelodysplastic syndrome. Blood105, 3731–3736 (2005).
  • Cassinat B , C Bellanne-Chantelot, A Notz-Carrere et al.: Screening for G-CSF receptor mutations in patients with secondary myeloid or lymphoid transformation of severe congenital neutropenia. A report from the French neutropenia register. Leukemia18, 1553–1555 (2004).
  • Schnittger S , KohlTM, LeopoldN et al.: D324N single nucleotide polymorphism in the FLT3 gene is associated with higher risk of myeloid leukemias. Genes Chromosomes Cancer45, 332–337 (2006).
  • Ridge SA , WorwoodM, OscierD, JacobsA, PaduaRA: FMS mutations in myelodysplastic, leukemic, and normal subjects.Proc. Natl Acad. Sci. USA87, 1377–1380 (1990).
  • Leroy H , RoumierC, N Grardel-Duflos et al.: Unlike AML1, CBFβ gene is not deregulated by point mutations in acute myeloid leukemia and in myelodysplastic syndromes. Blood99, 3848–3850 (2002).
  • Eguchi M , Eguchi-IshimaeM, GreavesM: Molecular pathogenesis of MLL-associated leukemias.Int. J. Hematol.82, 9–20 (2005).
  • Jamal R , GaleRE, ShaunN, ThomasB, WheatleyK, LinchDC: The retinoblastoma gene (RB1) in acute myeloid leukaemia: analysis of gene rearrangements, protein expression and comparison of disease outcome.Br. J. Haematol.94, 342–351 (1996).
  • Davis JN , McGheeL, MeyersS: The ETO (MTG8) gene family.Gene303, 1–10 (2003).
  • Nucifora G , L Laricchia-Robbio, Senyuk V: EVI1 and hematopoietic disorders: History and perspectives. Gene368, 1–11 (2006).
  • Bellanne-Chantelot C , ClauinS, LeblancT et al.: Mutations in the ELA2 gene correlate with more severe expression of neutropenia: a study of 81 patients from the French Neutropenia Register. Blood103, 4119–4125 (2004).
  • Tanner SM , AustinJL, LeoneG et al.: BAALC, the human member of a novel mammalian neuroectoderm gene lineage, is implicated in hematopoiesis and acute leukemia. Proc. Natl Acad. Sci. USA98, 13901–13906 (2001).
  • Abramovich C , HumphriesRK: Hox regulation of normal and leukemic hematopoietic stem cells.Curr. Opin. Hematol.12, 210–216 (2005).
  • Thiede C , KochS, CreutzigE et al.: Prevalence and prognostic impact of NPM1 mutations in 1485 adult patients with acute myeloid leukemia (AML). Blood107(10), 4011–4020 (2006).
  • Ellis NA , GrodenJ, YeTZ et al.: The Bloom's syndrome gene product is homologous to RecQ helicases. Cell83, 655–666 (1995).
  • Vulliamy TJ , MarroneA, KnightSW, Walne A, Mason PJ, Dokal I: Mutations in dyskeratosis congenita: their impact on telomere length and the diversity of clinical presentation. Blood107(7), 2680–2685 (2005).
  • Majeed F , JadkoS, FreedmanMH, DrorY: Mutation analysis of SBDS in pediatric acute myeloblastic leukemia.Pediatr. Blood Cancer45, 920–924 (2005).
  • Derry JM , OchsHD, FranckeU: Isolation of a novel gene mutated in Wiskott-Aldrich syndrome.Cell78, 635–644 (1994).

Website

  • Washington University School of Medicine CREATE Pharmacogentic Research Network website. http://pharmacogenetics.wustl.edu

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.